Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
NBIX [NASD]
Neurocrine Biosciences, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E16.44 EPS (ttm)4.57 Insider Own0.40% Shs Outstand94.70M Perf Week-5.20%
Market Cap6.91B Forward P/E25.25 EPS next Y2.97 Insider Trans-15.22% Shs Float93.04M Perf Month-11.30%
Income444.80M PEG1.36 EPS next Q0.57 Inst Own97.40% Short Float3.03% Perf Quarter-27.79%
Sales1.07B P/S6.46 EPS this Y977.20% Inst Trans0.24% Short Ratio3.18 Perf Half Y-23.77%
Book/sh14.21 P/B5.29 EPS next Y88.71% ROA23.60% Target Price118.86 Perf Year-35.76%
Cash/sh8.33 P/C9.02 EPS next 5Y12.10% ROE35.90% 52W Range71.88 - 120.27 Perf YTD-11.82%
Dividend- P/FCF21.43 EPS past 5Y42.90% ROI30.80% 52W High-37.56% Beta0.80
Dividend %- Quick Ratio4.30 Sales past 5Y121.20% Gross Margin98.80% 52W Low4.49% ATR3.45
Employees845 Current Ratio4.50 Sales Q/Q14.50% Oper. Margin18.00% RSI (14)38.54 Volatility4.16% 4.00%
OptionableYes Debt/Eq0.00 EPS Q/Q137.30% Profit Margin41.60% Rel Volume1.36 Prev Close72.80
ShortableYes LT Debt/Eq0.25 EarningsFeb 10 AMC Payout0.00% Avg Volume884.72K Price75.10
Recom2.10 SMA20-7.03% SMA50-10.00% SMA200-19.29% Volume1,203,029 Change3.16%
Jan-18-22Downgrade RBC Capital Mkts Outperform → Sector Perform $122 → $90
Nov-19-21Initiated BMO Capital Markets Underperform $76
Nov-17-21Upgrade JP Morgan Neutral → Overweight $124
Oct-14-21Downgrade Morgan Stanley Overweight → Equal-Weight $110 → $112
Sep-23-21Resumed Needham Hold
Aug-06-21Downgrade Canaccord Genuity Buy → Hold
May-18-21Resumed Goldman Neutral $108
May-06-21Upgrade Barclays Equal Weight → Overweight $110
Feb-02-21Initiated Raymond James Outperform $163
Sep-30-20Initiated The Benchmark Company Hold
Aug-04-20Downgrade JP Morgan Overweight → Neutral $136
Jun-29-20Downgrade Goldman Buy → Neutral $135
Jun-09-20Initiated Wedbush Outperform $147
Mar-06-20Initiated Citigroup Buy $124
Feb-27-20Initiated Barclays Equal Weight $105
Feb-24-20Initiated William Blair Outperform
Feb-06-20Initiated Mizuho Neutral
Feb-05-20Reiterated H.C. Wainwright Buy $102 → $125
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $110
Aug-07-19Initiated RBC Capital Mkts Outperform $118
Jan-12-22 05:38PM  
Harbour Capital Advisors, LLC Buys Diamondback Energy Inc, Realty Income Corp, Axalta Coating ...
GuruFocus.com
10:43AM  
Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine
Benzinga
Jan-06-22 04:01PM  
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones
PR Newswire
Jan-03-22 04:01PM  
Neurocrine Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
PR Newswire
Dec-28-21 07:38AM  
Stock Portfolio Buys ConocoPhillips, Neurocrine Biosciences Inc, Deckers Outdoor Corp, Sells ...
GuruFocus.com
Dec-17-21 10:38PM  
Goldman Sachs Variable Insurance Trust Large Cap Value Fund Buys Salesforce. ...
GuruFocus.com
Dec-14-21 11:38PM  
VanEck Biotech ETF Buys Icon PLC, Bio-Techne Corp, Natera Inc, Sells , Neurocrine Biosciences ...
GuruFocus.com
Dec-10-21 01:36PM  
Neurocrine Biosciences, Inc. (NBIX) Fell Out Of Favor With Hedge Funds
Insider Monkey
Dec-09-21 08:16AM  
Here's Why I Think Neurocrine Biosciences (NASDAQ:NBIX) Is An Interesting Stock
Simply Wall St.
Dec-08-21 07:38PM  
Tekla Healthcare Investors Buys Amgen Inc, Guardant Health Inc, Icon PLC, Sells Abbott ...
GuruFocus.com
Dec-07-21 04:35PM  
Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease
PR Newswire
Dec-06-21 11:32AM  
15 Best Stocks to Buy for 2022 According to Analysts
Insider Monkey
Nov-30-21 04:05PM  
Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer
PR Newswire
Nov-22-21 08:00AM  
Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders
PR Newswire
Nov-09-21 04:01PM  
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
PR Newswire
Nov-02-21 03:14PM  
Why Neurocrine Biosciences Shares Fell Nearly 10% Today
Motley Fool -10.02%
Nov-01-21 10:00PM  
Neurocrine Biosciences, Inc (NBIX) Q3 2021 Earnings Call Transcript
Motley Fool
05:15PM  
Neurocrine Biosciences (NBIX) Lags Q3 Earnings Estimates
Zacks
04:01PM  
Neurocrine Biosciences Reports Third Quarter 2021 Financial Results
PR Newswire
08:00AM  
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data at Psych Congress 2021
PR Newswire
Oct-26-21 10:36AM  
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Simply Wall St.
Oct-25-21 03:01PM  
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks
Oct-18-21 12:31PM  
Hedge Funds Are Coming Back To Neurocrine Biosciences, Inc. (NBIX)
Insider Monkey
Oct-16-21 05:00PM  
Neurocrine Biosciences to Present ONGENTYS® (opicapone) and INGREZZA® (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting
PR Newswire
Oct-13-21 11:30AM  
Notable Neurocrine Biosciences Insider Trades $1.1M In Company Stock
Benzinga
Oct-11-21 04:01PM  
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2021 Financial Results
PR Newswire
Oct-08-21 07:29AM  
Neurocrine Biosciences Expands Monumental Moments Program With World-Renowned Artist Jorge Rodriguez-Gerada to Raise Mental Health Awareness and Honor Those Impacted by the Pandemic
PR Newswire
Sep-20-21 08:52AM  
Those who invested in Neurocrine Biosciences (NASDAQ:NBIX) five years ago are up 79%
Simply Wall St.
Sep-10-21 09:23AM  
Neurocrine Biosciences to Present New INGREZZA® (valbenazine) and ONGENTYS® (opicapone) Data at the MDS Virtual Congress 2021
PR Newswire
Sep-08-21 08:30AM  
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone
GlobeNewswire
Sep-02-21 04:13PM  
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
PR Newswire
Aug-05-21 04:01PM  
Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease
PR Newswire
06:14AM  
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Simply Wall St.
Aug-03-21 10:31PM  
Neurocrine Biosciences, inc (NBIX) Q2 2021 Earnings Call Transcript
Motley Fool
05:25PM  
Neurocrine Biosciences (NBIX) Q2 Earnings Miss Estimates
Zacks
04:01PM  
Neurocrine Biosciences Reports Second Quarter 2021 Financial Results
PR Newswire
Jul-27-21 03:03PM  
Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out for
Zacks
Jul-22-21 12:10PM  
Hedge Funds Never Been Less Bullish On Neurocrine Biosciences, Inc. (NBIX)
Insider Monkey
Jul-19-21 04:01PM  
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results
PR Newswire
Jul-08-21 04:01PM  
Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference
PR Newswire
Jul-06-21 11:49AM  
10 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman
Insider Monkey
Jun-21-21 05:53AM  
Subdued Growth No Barrier To Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price
Simply Wall St.
Jun-01-21 04:01PM  
Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
PR Newswire
May-11-21 04:01PM  
Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference
PR Newswire
May-06-21 06:14AM  
Is Neurocrine Biosciences (NASDAQ:NBIX) Using Too Much Debt?
Simply Wall St.
12:01AM  
Neurocrine Biosciences Inc (NBIX) Q1 2021 Earnings Call Transcript
Motley Fool
May-05-21 05:15PM  
Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Miss Estimates
Zacks
04:01PM  
Neurocrine Biosciences Reports First Quarter 2021 Financial Results
PR Newswire
02:45PM  
Neurocrine Biosciences, Inc. to Host Earnings Call
ACCESSWIRE
May-04-21 04:01PM  
Neurocrine Biosciences to Present at the Bank of America 2021 Healthcare Conference
PR Newswire
May-03-21 08:30AM  
Neurocrine Biosciences Supports Mental Health Month and Tardive Dyskinesia Awareness Week
PR Newswire
Apr-28-21 12:34PM  
Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out for
Zacks
Apr-26-21 04:01PM  
Sentia Medical Sciences and Neurocrine Biosciences Enter into Strategic Collaboration to Discover Novel CRF Peptides
GlobeNewswire
Apr-19-21 03:51PM  
Is NBIX Stock A Buy or Sell?
Insider Monkey
Apr-16-21 09:00AM  
Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors
PR Newswire
Apr-14-21 04:01PM  
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results
PR Newswire
Apr-08-21 04:01PM  
Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual Meeting
PR Newswire
Mar-26-21 09:33AM  
Strength Seen in Neurocrine (NBIX): Can Its 11.1% Jump Turn into More Strength?
Zacks
Mar-25-21 04:01PM  
Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day
PR Newswire +11.07%
03:34PM  
Why Neurocrine Biosciences Stock Jumped Today
Motley Fool
Mar-24-21 06:35PM  
Neurocrine Biosciences Set to Join S&P MidCap 400; O-I Glass to Join S&P SmallCap 600
PR Newswire
Mar-22-21 07:21AM  
Introducing Neurocrine Biosciences (NASDAQ:NBIX), The Stock That Zoomed 161% In The Last Five Years
Simply Wall St.
Mar-20-21 11:00AM  
Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021
PR Newswire
Mar-18-21 06:02PM  
Top Biotech Stocks for Q2 2021
Investopedia
Mar-09-21 04:01PM  
Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference
PR Newswire
Mar-02-21 08:53AM  
Neurocrine/Takeda's Luvadaxistat Fails To Improve Schizophrenia Symptom Severity
Benzinga -7.32%
07:30AM  
Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)
PR Newswire
Feb-23-21 04:01PM  
Neurocrine Biosciences to Present at the Cowen 41st Annual Health Care Conference
PR Newswire
Feb-04-21 11:31PM  
Neurocrine Biosciences Inc (NBIX) Q4 2020 Earnings Call Transcript
Motley Fool
05:55PM  
Neurocrine Biosciences (NBIX) Q4 Earnings Top Estimates
Zacks
04:49PM  
Recap: Neurocrine Biosciences Q4 Earnings
Benzinga
04:01PM  
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results
PR Newswire
02:45PM  
Neurocrine Biosciences, Inc. to Host Earnings Call
ACCESSWIRE
04:00AM  
Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Latest Stock Performance A Reflection Of Its Financial Health?
Simply Wall St.
Feb-02-21 04:01PM  
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
GlobeNewswire +7.00%
Jan-28-21 12:32PM  
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
Zacks
Jan-20-21 04:01PM  
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results
PR Newswire
Jan-08-21 10:15AM  
Neurocrine Biosciences Shares Rise Despite Disappointing Q4 Earnings; Target Price $121
FX Empire +9.00%
07:30AM  
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
PR Newswire
Jan-04-21 04:01PM  
Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
PR Newswire
Dec-22-20 04:17PM  
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
GlobeNewswire
Dec-21-20 11:36AM  
Is NBIX A Good Stock To Buy Now?
Insider Monkey
04:22AM  
Should You Be Adding Neurocrine Biosciences (NASDAQ:NBIX) To Your Watchlist Today?
Simply Wall St.
Dec-11-20 08:58AM  
Is Neurocrine Biosciences (NBIX) a Smart Long-term Buy?
Insider Monkey
Dec-09-20 07:51AM  
New Strong Sell Stocks for December 9th
Zacks
Nov-19-20 09:00AM  
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
PR Newswire
08:00AM  
Neurocrine Biosciences Announces Repurchase of Convertible Notes
PR Newswire
Nov-13-20 07:29AM  
Results: Neurocrine Biosciences, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
Simply Wall St.
Nov-10-20 04:00PM  
Neurocrine Biosciences Inc (NBIX) Q3 2020 Earnings Call Transcript
Motley Fool -14.81%
Nov-09-20 05:15PM  
Neurocrine Biosciences (NBIX) Reports Q3 Loss, Lags Revenue Estimates
Zacks +6.72%
04:54PM  
Recap: Neurocrine Biosciences Q3 Earnings
Benzinga
04:01PM  
Neurocrine Biosciences Reports Third Quarter 2020 Financial Results
PR Newswire
02:45PM  
Neurocrine Biosciences, Inc. to Host Earnings Call
ACCESSWIRE
09:00AM  
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
PR Newswire
Nov-06-20 10:18AM  
Preview: Neurocrine Biosciences's Earnings
Benzinga
Nov-04-20 11:10AM  
Was The Smart Money Wrong About Neurocrine Biosciences, Inc. (NBIX)?
Insider Monkey +13.00%
Nov-02-20 12:31PM  
Earnings Preview: Neurocrine Biosciences (NBIX) Q3 Earnings Expected to Decline
Zacks
11:45AM  
Neurocrine (NBIX) to Report Q3 Earnings: What's in Store?
Zacks
Oct-19-20 07:56AM  
New Strong Sell Stocks for October 19th
Zacks
Oct-15-20 10:45AM  
Is Neurocrine Biosciences (NASDAQ:NBIX) Using Too Much Debt?
Simply Wall St.
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL A Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBERTS EIRYChief Medical OfficerJan 10Sale74.502,632196,08821,279Jan 12 05:53 PM
Gano KyleChief Business Development OffJan 05Option Exercise8.6628,266244,784133,250Jan 07 06:04 PM
Gano KyleChief Business Development OffJan 05Sale85.5028,2662,416,751104,984Jan 07 06:04 PM
ABERNETHY MATTChief Financial OfficerDec 01Sale82.591,645135,85216,349Dec 03 05:02 PM
Grigoriadis Dimitri E.Chief Research OfficerOct 07Option Exercise43.245,000216,20087,273Oct 12 06:32 PM
LYONS GARY ADirectorOct 07Sale105.065,000525,294208,697Oct 12 06:34 PM
Grigoriadis Dimitri E.Chief Research OfficerOct 07Sale104.818,000838,51082,273Oct 12 06:32 PM
Cooke JulieChief Human Resources OfficerOct 04Sale101.73987100,40814,841Oct 06 04:37 PM
BENEVICH ERICChief Commercial OfficerAug 16Sale89.625,628504,39515,608Aug 18 06:18 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJul 27Sale93.8016,7091,567,33615,801Jul 29 05:32 PM
LYONS GARY ADirectorJun 10Sale100.2710,0001,002,743213,697Jun 14 08:25 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Option Exercise35.991,70061,18333,610Feb 12 08:27 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Sale119.961,700203,92632,510Feb 12 08:27 PM
Lippoldt DarinChief Legal OfficerFeb 09Option Exercise35.9936,1941,302,62264,361Feb 09 09:16 PM
Lippoldt DarinChief Legal OfficerFeb 09Sale116.1736,1944,204,83134,361Feb 09 09:16 PM
Lippoldt DarinChief Legal OfficerFeb 08Sale116.723,407397,67431,914Feb 09 09:16 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 08Sale116.7510,4661,221,864446,144Feb 09 09:17 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 08Sale116.692,708315,99983,456Feb 09 09:18 PM
ROBERTS EIRYChief Medical OfficerFeb 08Sale116.782,363275,94417,231Feb 09 09:21 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 08Sale116.813,261380,92930,437Feb 09 09:20 PM
Cooke JulieChief Human Resources OfficerFeb 08Sale116.731,338156,18912,915Feb 09 09:24 PM
BENEVICH ERICChief Commercial OfficerFeb 08Sale116.824,270498,84218,018Feb 09 09:26 PM
ABERNETHY MATTChief Financial OfficerFeb 08Sale116.822,910339,94213,043Feb 09 09:30 PM
Bozigian Haig P.Chief Development OfficerFeb 08Sale116.803,842448,749154,934Feb 09 09:27 PM
Gano KyleChief Business Development OffFeb 08Sale116.853,693431,518102,406Feb 09 09:42 PM
Gano KyleChief Business Development OffFeb 05Sale114.002,677305,18498,663Feb 09 09:42 PM
Bozigian Haig P.Chief Development OfficerFeb 05Sale113.7970480,109153,328Feb 09 09:27 PM
BENEVICH ERICChief Commercial OfficerFeb 05Sale114.0380992,24716,434Feb 09 09:26 PM
Cooke JulieChief Human Resources OfficerFeb 05Sale113.8660568,88612,125Feb 09 09:24 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 05Sale114.1586598,73929,675Feb 09 09:20 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 05Sale113.7660568,82382,169Feb 09 09:18 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 05Sale114.162,422276,504443,249Feb 09 09:17 PM
Lippoldt DarinChief Legal OfficerFeb 05Sale114.0560569,00330,627Feb 09 09:16 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 26Option Exercise35.991,10039,58929,602Jan 27 09:30 PM
BENEVICH ERICChief Commercial OfficerJan 26Option Exercise41.7830012,53416,105Jan 27 08:58 PM
BENEVICH ERICChief Commercial OfficerJan 26Sale120.0040048,00015,705Jan 27 08:58 PM
LYONS GARY ADirectorJan 26Sale120.0040048,000223,697Jan 27 09:53 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 26Sale119.971,100131,96529,002Jan 27 09:30 PM
BENEVICH ERICChief Commercial OfficerJan 25Option Exercise41.783,477145,26920,882Jan 27 08:58 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 25Option Exercise34.4617,570605,47037,960Jan 27 09:30 PM
BENEVICH ERICChief Commercial OfficerJan 25Sale120.035,077609,37115,805Jan 27 08:58 PM
LYONS GARY ADirectorJan 25Sale120.031,600192,047224,097Jan 27 09:53 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 25Sale119.9717,5702,107,81229,002Jan 27 09:30 PM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2022 FINVIZ.com. All Rights Reserved.